Chris Eccles

Senior Research Analyst

Chris provides our investment teams with valuable insight across all healthcare sectors globally, specialising in regulatory affairs and biopharmaceuticals.

He started his finance career at Morgan Stanley, securing a European-focused pharmaceutical analyst role in 2011 after completing an internship with the firm a year earlier. After three years, he joined long/short equity hedge fund Kola Capital as a Senior Analyst before going on to work for Stifel in 2017 as a healthcare specialist.

Chris holds a first-class bachelor’s degree in Physiological Sciences from Oxford University.

Scroll to top
To get started, please select your location and investor type below.

If you are invested in Impax Funds – regardless of share class (Investor, Institutional, or Class A) or account type (individual, business or other entity) please select Impax Funds Investor as your Investor Type.

Access Impax Asset Management Limited’s Form CRS here.

Important Information

I confirm that I am an [investor_type] based in [investor_country] and that I have read and understood the important information, privacy policy and terms and conditions which govern the use of this website.

Risk Warning

Capital at risk. The value of investments may go up or down and is not guaranteed.